Synthesis and Anticancer Activity of N-(di/trimethoxyaryl)-5-arylisoxazole-3-carboxamide

References

• L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global Cancer Statistics, 2012,” CA: A Cancer Journal for Clinicians 65, no. 2 (2015): 87–108.
   PubMed Web of Science ®Google Scholar
• X. Ke, and L. Shen, “Molecular Targeted Therapy of Cancer: The Progress and Future Prospect,” Frontiers in Laboratory Medicine 1, no. 2 (2017): 69–75.
   Google Scholar
• S. W. Fesik, “Promoting Apoptosis as a Strategy for Cancer Drug Discovery,” Nature Reviews. Cancer 5, no. 11 (2005): 876–85.
   PubMed Web of Science ®Google Scholar
• R. Gerl, and D. L. Vaux, “Apoptosis in the Development and Treatment of Cancer,”Carcinogenesis 26, no. 2 (2005): 263–70.
   PubMed Web of Science ®Google Scholar
• (a) A. Sysak, and B. Obmińska-Mrukowicz, “Isoxazole Ring as a Useful Scaffold in a Search for New Therapeutic Agents,” European Journal of Medicinal Chemistry 137 (2017): 292–309. (b) H. Dai, W. Yao, Y. Fang, S. Y. Sun, Y. J. Shi, J. Chen, G. Q. Jiang, and J. Shi, “Design, Synthesis and Bioactivities of Novel Isoxazole-Containing Pyrazole Oxime Derivatives,”Molecules 22, no. 12 (2017): 2000. (c) H. Dai, W. Yao, L. Y. Ye, Y. Fang, Y. J. Shi, C. Song, C. J. Li, and J. Shi, “Synthesis and Biological Activities of Novel Pyrazole Amide Derivatives Containing Substituted Isoxazole Group,” Chinese Journal of Chemistry 37, no. 8 (2017): 2165–71.
   PubMed Web of Science ®Google Scholar
• S. Y. Sharp, C. Prodromou, K. Boxall, M. V. Powers, J. L. Holmes, G. Box, T. P. Matthews, K.-M J. Cheung, A. Kalusa, K. James, et al. “Inhibition of the Heat Shock Protein 90 Molecular Chaperone in Vitro and in Vivo by Novel, synthetic, potent Resorcinylic Pyrazole/Isoxazole Amide Analogues,” Molecular Cancer Therapeutics 6, no. 4 (2007): 1198–211.
   PubMed Web of Science ®Google Scholar
• (a)M. R. Jensen, J. Schoepfer, T. Radimerski, A. Massey, C. T. Guy, J. Brueggen, C. Quadt, A. Buckler, R. Cozens, M. J. Drysdale, et al. “NVP-AUY922: a Small Molecule HSP90 Inhibitor with Potent Antitumor Activity in Preclinical Breast Cancer Models,” Breast Cancer Research 10, (2008): R33. (b) B. Çalışkan, E. Sinoplu, K. İbiş, E. A. Güzelcan, R. Ç. Atalay, and E. Banoglu, “Synthesis and Cellular Bioactivities of Novel Isoxazole Derivatives Incorporating an Arylpiperazine Moiety as Anticancer Agents,” Journal of Enzyme Inhibition and Medicinal Chemistry 33, no. 1 (2018): 1352–61.
   PubMed Web of Science ®Google Scholar
• A. Padmaja, T. Payani, G. Dinneswara Reddy, and V. Padmavathi, “Synthesis, Antimicrobial and Antioxidant Activities of Substituted Pyrazoles, Isoxazoles, Pyrimidine and Thioxopyrimidine Derivatives,” European Journal of Medicinal Chemistry 44, no. 11 (2009): 4557–66.
   PubMed Web of Science ®Google Scholar
• Y. S. Lee, and B. H. Kim, “Heterocyclic Nucleoside Analogues: Design and Synthesis of Antiviral, Modified Nucleosides Containing Isoxazole Heterocycles,” Bioorganic & Medicinal Chemistry Letters 12, no. 10 (2002): 1395–7.
   PubMed Web of Science ®Google Scholar
• F. Li, Y. Hu, Y. Wang, C. Ma, and J. Wang, “Expeditious Lead Optimization of Isoxazole-Containing Influenza a Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-coupling Reaction,” Journal of Medicinal Chemistry 60, no. 4 (2017): 1580–90.
   PubMed Web of Science ®Google Scholar
• S. Ryng, M. Zimecki, M. Maczynski, G. Chodaczek and M. Kocieba, “Immunosuppressive Activity of an Isoxazolo[5,4-e]triazepine-Compound RM33. I. Effects on the Humoral and Cellular Immune Response in Mice,” Pharmacological Reports 57 (2005): 195–202.
   PubMed Web of Science ®Google Scholar
• P. Vitale, M. G. Perrone, P. Malerba, A. Lavecchia, and A. Scilimati, “Selective COX-1 Inhibition as a Target of Theranostic Novel Diarylisoxazoles,” European Journal of Medicinal Chemistry 74 (2014): 606–18.
   PubMed Web of Science ®Google Scholar
• S. Batra, T. Srinivasan, S. K. Rastogi, B. Kundu, A. Patra, A. P. Bhaduri, and M. Dixit, “Combinatorial Synthesis and Biological Evaluation of Isoxazole-based Libraries as Antithrombotic Agents,” Bioorganic & Medicinal Chemistry Letters 12, no. 15 (2002): 1905–8.
   PubMed Web of Science ®Google Scholar
• M. Gutiérrez, J. Amigo, E. Fuentes, I. Palomo, and L. Astudillo, “Synthetic Isoxazole as Antiplatelet Agent,”Platelets 25, no. 4 (2014): 234–8.
   PubMed Web of Science ®Google Scholar
• A. A. Abu-Hashem, and M. El-Shazly, “Synthesis of New Isoxazole-, Pyridazine-, Pyrimidopyrazines and Their Anti-inflammatory and Analgesic Activity,”Medicinal Chemistry 14, no. 4 (2018): 356–71.
   PubMed Web of Science ®Google Scholar
• L. Y. Yang, J. Zhang, L. H. Si, L. Han, B. Zhang, H. Ma, J. H. Xing, L. L. Zhao, J. P. Zhou, and H. B. Zhang, “Synthesis and Biological Evaluation of GPR40/FFAR1 Agonists Containing 3,5-Dimethylisoxazole,” European Journal of Medicinal Chemistry 116 (2016): 46–58.
   PubMed Web of Science ®Google Scholar
• N. D. Eddington, D. S. Cox, R. R. Roberts, R. J. Butcher, I. O. Edafiogho, J. P. Stables, N. Cooke, A. M. Goodwin, C. A. Smith, and K. R. Scott, “Synthesis and Anticonvulsant Activity of Enaminones. 4. Investigations on Isoxazole Derivatives,” European Journal of Medicinal Chemistry 37, no. 8 (2002): 635–48.
   PubMed Web of Science ®Google Scholar
• R. Narlawar, M. Pickhardt, S. Leuchtenberger, K. Baumann, S. Krause, T. Dyrks, S. Weggen, E. Mandelkow, and B. Schmidt, “Curcumin-Derived Pyrazoles and Isoxazoles: Swiss Army Knives or Blunt Tools’ for Alzheimer’s Disease?,” ChemMedChem 3, no. 1 (2008): 165–72.
   PubMed Web of Science ®Google Scholar
• Z. Najafi, M. Mahdavi, M. Saeedi, R. Sabourian, M. Khanavi, M. Safavi, M. B. Tehrani, A. Shafiee, A. Foroumadi, and T. Akbarzadeh, “1,2,3-Triazole-Isoxazole Based Acetylcholinesterase Inhibitors: Synthesis, Biological Evaluation and Docking Study,” Letters in Drug Design & Discovery 14, no. 1 (2017): 58–65.
   Web of Science ®Google Scholar
• J. Kaffy, R. Pontikis, D. Carrez, A. Croisy, C. Monneret, and J. C. Florent, “Isoxazole Type Derivatives Related to Combretastatin A-4, Synthesis and Biological Evaluation,” Bioorganic & Medicinal Chemistry 14, no. 12 (2006): 4067–77.
   PubMed Web of Science ®Google Scholar
• P. Poma, M. Notarbartolo, M. Labbozzetta, A. Maurici, V. Carina, A. Alaimo, M. Rizzi, D. Simoni, and N. D'Alessandro, “The Antitumor Activities of Curcumin and of Its Isoxazole Analogue Are Not Affected by Multiple Gene Expression Changes in an MDR Model of the MCF-7 Breast Cancer Cell Line: analysis of the Possible Molecular Basis,” International Journal of Molecular Medicine 20 (2007): 329–35.
   PubMed Web of Science ®Google Scholar
• A. Kamal, E. Vijaya Bharathi, J. Surendranadha Reddy, M. Janaki Ramaiah, D. Dastagiri, M. Kashi Reddy, A. Viswanath, T. Lakshminarayan Reddy, T. Basha Shaik, S. N. C. V. L. Pushpavalli, et al. “Synthesis and Biological Evaluation of 3,5-Diaryl Isoxazoline/Isoxazole Linked 2,3-Dihydroquinazolinone Hybrids as Anticancer Agents,” European Journal of Medicinal Chemistry 46, no. 2 (2011): 691–703.
   PubMed Web of Science ®Google Scholar
• T. Taldone, A. Gozman, R. Maharaj, and G. Chiosis, “Targeting Hsp90: Small Molecule Inhibitors and Their Clinical Development,” Current Opinion in Pharmacology 8, no. 4 (2008): 370–4.
   PubMed Web of Science ®Google Scholar
• Z. Najafi, M. Mahdavi, M. Safavi, M. Saeedi, H. Alinezhad, M. Pordeli, S. Kabudanian Ardestani, A. Shafiee, A. Foroumadi, and T. Akbarzadeh, “Synthesis and In Vitro Cytotoxic Activity of Novel Triazole-isoxazole Derivatives,” Journal of Heterocyclic Chemistry 52, no. 6 (2015): 1743–7.
   Web of Science ®Google Scholar
• F. Vafadarnejad, M. Saeedi, M. Mahdavi, A. Rafinejad, E. Karimpour-Razkenari, B. Sameem, M. Khanavi, and T. Akbarzadeh, “Novel Indole-isoxazole Hybrids: Synthesis and in Vitro anti-cholinesterase Activity,” Letters in Drug Design & Discovery 14 (2017): 58–65.
   Web of Science ®Google Scholar
• T. Akbarzadeh, S. Noushini, S. Taban, M. Mahdavi, M. Khoshneviszadeh, M. Saeedi, S. Emami, M. Eghtedari, Y. Sarrafi, M. Khoshneviszadeh, et al. “Synthesis and Cytotoxic Activity of Novel Poly-substituted Imidazo[2,1-c][1,2,4]triazin-6-Amines,” Molecular Diversity 19, no. 2 (2015): 273–81.
   PubMed Web of Science ®Google Scholar
• M. Mohammadi-Khanaposhtani, M. Safavi, R. Sabourian, M. Mahdavi, M. Pordeli, M. Saeedi, S. K. Ardestani, A. Foroumadi, A. Shafiee, and T. Akbarzadeh, “Design, Synthesis, In Vitro Cytotoxic Activity Evaluation, and Apoptosis-induction Study of New 9(10H)-Acridinone-1,2,3-Triazoles,” Molecular Diversity 19, no. 4 (2015): 787–95.
   PubMed Web of Science ®Google Scholar
• T. Mosmann, “Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays,” Journal of Immunological Methods 65, no. 1–2 (1983): 55–63.
   PubMed Web of Science ®Google Scholar
• M. Safavi, A. Ashtari, F. Khalili, S. S. Mirfazli, M. Saeedi, S. K. Ardestani, P. R. Ranjbar, M. B. Tehrani, B. Larijani, and M. Mahdavi, “Novel Quinazolin‐4(3H)‐One Linked to 1,2, 3‐Triazoles: Synthesis and Anticancer Activity,” Chemical Biology & Drug Design 92, no. 1 (2): 1373–81.
   Google Scholar
• J. Stamos, M. X. Sliwkowski, and C. Eigenbrot, “Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor,” The Journal of Biological Chemistry 277, no. 48 (2002): 46265–72.
   PubMed Web of Science ®Google Scholar